Healthtech investing: Battle of the heavyweights
SB would like to cordially invite you to our Special Investor Forum, featuring heavyweight investors, Josh Makower and Yoh-Chie Lu, who will go head-to head with investing knowhow in the US vs Asia respectively. Details of the forum can be found below.
Date: Thursday, 30 May 2019
Time: 1200Hrs - 1400Hrs (Registration starts at 1130Hrs)
Venue: Multi-Purpose Hall @ Innovis, 2 Fusionopolis Way, Singapore 138634
Event Flyer: Click here to download
This forum aims to bring to light healthcare investing from a serial investor’s point of view and will cover the company’s impact investing strategy, successes and lessons learned, and whether this approach still holds true for emerging industry trends and if it can be replicated for other markets. In particular, both speakers will endeavor to share their thoughts on country specific opportunities across the various healthcare segments, valuation and due-diligence requirements unique to specific countries.
The forum will be beneficial to all stakeholders of the Medtech/healthtech Innovation ecosystem who are looking to move their projects into the next phase of fund-raising and commercialization. All are welcome!
Speaker: Dr. Josh Makower, General Partner, NEA
|Josh is a General Partner on NEA's healthcare team leading their medtech/healthtech practice. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years. Notable transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex in 2017, Nuelle, acquired by Aytu in 2017, Acclarent, acquired by J&J in 2009, EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. On-going ExploraMed/NEA ventures include Moximed, Willow and Exploramed V. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh currently serves on the board of directors for DOTS Devices, Eargo, ExploraMed, Foundry Therapeutics, Intact Vascular, Intrinsic Therapeutics, Lungpacer, Moximed, Willow, SetPoint Medical, Vesper and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT.|
Speaker: Mr. Lu Yoh-Chie, General Partner, Majuven Pte Ltd
|Mr. Lu was the Founder of Biosensors International Group and served as its Chairman and CEO from inception to 2008. He retained his leadership position as Chairman of Biosensors from January 2008 until November 2016 after it was acquired by Citic for SGD$1.1B. Mr. Lu has more than 30 years' experience in the medical industry. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. Mr. Lu took the company to IPO in Nasdaq and it was subsequently sold to British Oxygen Corporation. He served as president of Asia-Pacific with British Oxygen until 1990. Mr. Lu is active in both international and local medical arena as an entrepreneurial angel investor. Mr. Lu is a General Partner at Majuven Pte Ltd; Foundry Singapore and a venture partner for medical sector at Vertex Venture Management Pte Ltd. With SPRING, Mr. Lu collaborates with Accuron Technologies Ltd (a wholly- owned subsidiary of Temasek) through the Sector Specific Accelerator program. Yoh-Chie serves on the board of directors for Earlens, Moximed, lvantis, Visterra P(acquired by Otsuka for $430M), and lnnoventures.|
Moderator: Dr. Joseph Mocanu, Managing Partner, Verge HealthTech Fund
|Joseph is the Managing Partner of Verge HealthTech Fund focusing on early stage healthcare technology companies relevant to emerging markets. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 14 healthcare technology companies to date.Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.|